Phytecs
Phytecs is a private Los Angeles-based biotechnology company founded in 2015 that researches therapeutic applications of the human endocannabinoid system, with 11–50 employees and no commercially disclosed products or revenue.
- Company typePrivate
- Founded2015
- HeadquartersLos Angeles, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Phytecs does
Phytecs is a private, for-profit biotechnology company founded in 2015 and headquartered in Los Angeles, California. According to its self-description, the company is focused on "unlocking the therapeutic potential of the endocannabinoid system," positioning it in the cannabinoid-based therapeutics or pharmaceutical research space. The company operates with a headcount of 11–50 employees, consistent with an early- to mid-stage biotech. Gary Hiller is listed as President.
No further operational details are available in the input data. The company's website (phytecs.com) currently displays a default cPanel hosting error page rather than corporate content, indicating either an inactive domain, a misconfigured server, or a relocation of digital assets. There are no disclosed products, services, technology platforms, pricing models, customer segments, partnerships, funding rounds, regulatory filings, or management team entries beyond the President. As a result, the business model, go-to-market approach, revenue mechanics, and technical architecture of Phytecs cannot be substantiated from the available evidence.
Phytecs firmographics
Firmographics- Name
- Phytecs
- Website
- https://phytecs.com
- Company type
- Private
- Founded year
- 2015
- Headcount range
- 11–50 employees
- Short description
- Phytecs is a private Los Angeles-based biotechnology company founded in 2015 that researches therapeutic applications of the human endocannabinoid system, with 11–50 employees and no commercially disclosed products or revenue.
- Ownership category
- akta.pro rank
Phytecs industry classification
Industry- Product category
- Cannabinoid Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Phytecs is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Markets served
Phytecs business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Phytecs product offering
Product offeringCore offering
Phytecs is focused on unlocking the therapeutic potential of the endocannabinoid system. The company operates as a biotechnology research entity working on advancing therapeutic applications derived from the endocannabinoid system, with implications for pharmaceutical and drug development efforts. Specific product candidates, formulation details, or commercialization offerings are not publicly disclosed in the available source data.
Differentiator
Problem solved
Functional benefit
Companies that use Phytecs
Customer profileIdeal customer profiles1 record
Phytecs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Phytecs partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights2 records
Phytecs competitors and assessment
Company assessmentDirect peers
- GW Pharmaceuticals (Jazz Pharmaceuticals): Developer of approved cannabinoid-based therapeutics (Sativex, Epidiolex) — the benchmark direct competitor in endocannabinoid-derived pharmaceutical drug discovery and commercialization, validating the ECS therapeutic thesis Phytecs is pursuing.
- Zynerba Pharmaceuticals: Clinical-stage developer of transdermal cannabinoid drug candidates (e.g., Zygel/ZYN002) for neurological and developmental disorders — closely comparable small-cap peer translating ECS biology into pharmaceutical products.
- Tetra Bio-Pharma: Clinical-stage cannabinoid-derived drug developer advancing cannabinoid-pharmaceutical candidates through FDA pathways — directly comparable small-cap peer pursuing ECS-targeted therapeutics.
- Skye Bioscience: Clinical-stage cannabinoid-based therapeutics developer focused on metabolic and inflammatory conditions via ECS modulation — a closely matched small-cap peer in the same therapeutic niche Phytecs targets.
- Botanix Pharmaceuticals: Developer of synthetic cannabinoid pharmaceutical products (e.g., BTX 1801 for skin diseases) — directly comparable small-cap biotech translating ECS biology into dermatology/anti-infective drug candidates.
- Corbus Pharmaceuticals: Clinical-stage biotech developing cannabinoid-derived drug candidates (e.g., lenabasum) targeting inflammatory and fibrotic diseases — directly comparable as an ECS-pathway therapeutics developer at similar scale to Phytecs.
Emerging players
- Aelis Farma: Pre-clinical/early-clinical biotech focused on CB1 receptor signaling modulators (CB1-SLiMs) for CNS and metabolic indications — directly comparable niche player targeting the same endocannabinoid receptor system Phytecs works on.
- Aneuvo Sciences: Early-stage company developing ECS-targeting therapeutics for neurological indications — partially overlapping peer in the same discovery stage and target class as Phytecs.
Broad incumbents
- Emerald Health Therapeutics: Cannabis-pharmaceutical company developing cannabinoid-based prescription drug candidates across multiple indications — broader incumbent operating in the same ECS-therapeutics market category as Phytecs.
- Tilray Brands (pharma division): Large cannabis and cannabinoid pharmaceutical company with FDA-registration activity around cannabinoid APIs and finished products — a broader incumbent spanning the ECS-therapeutic category where Phytecs competes.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Phytecs social profiles
Digital presencePhytecs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phytecs leadership team
Management profileNumber of profiles
Profiles1 record
Phytecs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phytecs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phytecs
What does Phytecs do?
Phytecs is focused on unlocking the therapeutic potential of the endocannabinoid system. The company operates as a biotechnology research entity working on advancing therapeutic applications derived from the endocannabinoid system, with implications for pharmaceutical and drug development efforts. Specific product candidates, formulation details, or commercialization offerings are not publicly disclosed in the available source data.
When was Phytecs founded?
Phytecs was founded in 2015. It employs 11 to 50 people.
Where is Phytecs based?
Phytecs is headquartered in Los Angeles, United States, in the North America region.
Who are Phytecs's main competitors?
Direct peers on record are GW Pharmaceuticals (Jazz Pharmaceuticals), Zynerba Pharmaceuticals, Tetra Bio-Pharma, Skye Bioscience, Botanix Pharmaceuticals and Corbus Pharmaceuticals. Emerging players are Aelis Farma and Aneuvo Sciences. Broad incumbents are Emerald Health Therapeutics and Tilray Brands (pharma division).
Does Phytecs have an API?
No public API is recorded for Phytecs.
What industry is Phytecs in?
Phytecs's product category is Cannabinoid Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.